Search results for "Somatostatin receptor"

showing 10 items of 20 documents

Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control

2018

Objective. In acromegaly, both lipotoxicity secondary to GH excess and insulin resistance have a significant impact on the liver. Ultrasonography has shown poor sensitivity in detecting hepatic steatosis and noninvasive methods have been proposed. We evaluated the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, and we correlated it with disease activity and insulin resistance. Design. Thirty-one patients with newly diagnosed acromegaly were studied at diagnosis and after 12 months of treatment with somatostatin receptor ligands. Methods. Glucose and insulin levels, surrogate estimates of insulin sensitivity, and hepatic steatosis through ultrasonography and …

0301 basic medicinemedicine.medical_specialtyArticle SubjectEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologySettore MED/13 - EndocrinologiaCorrelation03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceInternal medicineAcromegalymedicinelcsh:RC648-665Endocrine and Autonomic SystemsSomatostatin receptorbusiness.industryhepatic steatosisInsulinmedicine.diseaseDisease control030104 developmental biologyLipotoxicitySteatosisbusinessResearch ArticleInternational Journal of Endocrinology
researchProduct

Role of Octreoscan and Correlation with MR Imaging in Graves' Ophthalmopathy

1995

Since the identification of somatostatin receptors on lymphocytes, orbital infiltration with mononuclear cells in Graves' ophthalmopathy has provided a rationale for receptor imaging with the radiolabeled somatostatin analog Octreotide. In 40 patients with Graves' ophthalmopathy and 10 controls, 110 MBq indium-Octreotide were administered i.v., and scans were performed at 4 and 24 h after injection. An uptake ratio between the orbits and the brain was determined. In 20 ophthalmophathy patients, magnetic resonance imaging (MRI) of the orbits was performed and the T2 relaxation time was measured within the rectus muscles. Compared to controls (4 h Octreotide uptake: median 6.0 counts/pixel/MB…

AdultMaleendocrine systemPathologymedicine.medical_specialtyEndocrinology Diabetes and MetabolismOctreotidePeripheral blood mononuclear cellGraves' ophthalmopathyEndocrinologyInternal medicineHumansMedicineReceptors SomatostatinReceptorAgedTomography Emission-Computed Single-PhotonSomatostatin receptorbusiness.industryMiddle Agedmedicine.diseaseMagnetic Resonance ImagingMr imagingGraves Diseaseeye diseasesEndocrinologyOculomotor MusclesIsotope LabelingFemalebusinessInfiltration (medical)Thyroid
researchProduct

Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours

2019

Abstract Introduction [68Ga]Ga-DATA-TOC is a new radiolabelled somatostatin-analogue for positron emission tomography (PET) imaging of neuroendocrine tumours. Its advantage over DOTA-conjugated compounds is the possibility for high-efficiency labelling with gallium-68 quickly at room temperature with high reliability and without the need for product purification, which enables the development of an instant kit-type labelling method. We evaluated its imaging characteristics in patients with neuroendocrine tumours in comparison to [68Ga]Ga-DOTA-TOC. Methods 19 patients imaged with [68Ga]Ga-DATA-TOC were retrospectively analysed and uptake in normal tissues was compared with a group of 19 pati…

Cancer ResearchPET-CTBiodistributionmedicine.diagnostic_testSomatostatin receptorbusiness.industry030218 nuclear medicine & medical imagingLesion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSomatostatinchemistryPositron emission tomography030220 oncology & carcinogenesismedicineMolecular MedicineDOTARadiology Nuclear Medicine and imagingIn patientmedicine.symptombusinessNuclear medicineNuclear Medicine and Biology
researchProduct

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications.

2019

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supp…

Cancer Researchmedicine.medical_specialtypositron emission tomographymedicine.medical_treatmentReviewlcsh:RC254-282meningioma030218 nuclear medicine & medical imagingMeningioma03 medical and health sciences0302 clinical medicineNeuroimagingFunctional neuroimagingmedicineotorhinolaryngologic diseasesMedical diagnosisRadiation treatment planningGrading (tumors)neoplasmsMeningioma; Neuroimaging; Positron emission tomography; Radionuclide therapy; Somatostatin receptorneuroimagingbusiness.industryradionuclide therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasesomatostatin receptorOncologymeningioma; somatostatin receptor; neuroimaging; positron emission tomography; radionuclide therapy030220 oncology & carcinogenesisRadionuclide therapyRadiologybusinessWatchful waitingCancers
researchProduct

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly.

2011

ObjectiveThe aim of this study was to characterize the genetic variance of somatostatin receptor 5 (SSTR5) and investigate the possible correlation of such variants with acromegaly risk and different disease characteristics.Design and methodsThe SSTR5 gene coding region and 2000 bp upstream region was sequenced in 48 patients with acromegaly and 96 control subjects. Further, three single nucleotide polymorphisms (SNPs) were analyzed in the same group of acromegaly patients and in an additional group of 475 age- and sex-matched controls.ResultsIn total, 19 SNPs were identified in the SSTR5 gene locus by direct sequencing. Three SNPs (rs34037914, rs169068, and rs642249) were significantly ass…

Malemedicine.medical_specialty:MEDICINE [Research Subject Categories]Endocrinology Diabetes and MetabolismSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideSomatostatin receptorEndocrinologyInternal medicineAcromegalyDatabases GeneticmedicineHumansReceptors SomatostatinAlleleeducationAllele frequencyAllelesAgededucation.field_of_studySomatostatin receptor-5Polymorphism GeneticSomatostatin receptorReverse Transcriptase Polymerase Chain ReactionHaplotypeGeneral MedicineOdds ratioDNAMiddle Agedmedicine.diseaseLatviaHormonesEndocrinologyTreatment OutcomeHaplotypesAcromegalyClinical StudyFemaleEuropean journal of endocrinology
researchProduct

The rs1466113 Polymorphism in the Somatostatin Receptor 2 Gene Is Associated with Obesity and Food Intake in a Mediterranean Population

2009

<i>Background:</i> A genome-wide association study identified rs1466113 (G>C) in the somatostatin receptor 2 (SSTR2) gene as one of the polymorphisms most significantly associated with body mass index (BMI). As replication is required, we examined the association between this polymorphism and anthropometric variables and food intake in a Mediterranean population. <i>Methods:</i> We studied 945 high cardiovascular-risk subjects (340 men and 605 women) aged 67 ± 6 years, participating in the PREDIMED-Valencia Study. Demographic, clinical, biochemical, dietary, genetic and anthropometric data were obtained. <i>Results:</i> We found recessive effects for t…

Malemedicine.medical_specialtyGenotypePopulationMedicine (miscellaneous)BiologyNutrigeneticsBody Mass IndexEatingNutrigenomicsInternal medicineGenotypemedicineHumansSomatostatin receptor 2ObesityReceptors SomatostatineducationGeneAllelesAgededucation.field_of_studyPolymorphism GeneticNutrition and DieteticsMediterranean RegionBody WeightMiddle Agedmedicine.diseaseObesityDietCross-Sectional StudiesLogistic ModelsEndocrinologySomatostatinFemaleBody mass indexAnnals of Nutrition and Metabolism
researchProduct

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.

2020

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish pr…

Oncologymedicine.medical_specialtycatecholaminergic crisisMEDLINElcsh:Medicinecarcinoid syndrome030209 endocrinology & metabolismReviewNeuroendocrine tumors03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesystematic reviewInternal medicinemedicinecarcinoid crisisProgression-free survivalDOTA-TATEpeptide receptor radionuclide therapyhormonal crisisOctreotatebusiness.industrySomatostatin receptorlcsh:RGeneral Medicinemedicine.diseaseSystematic reviewchemistry030220 oncology & carcinogenesisneuroendocrine tumorsbusiness177Lu-DOTA-TATECarcinoid syndromeJournal of clinical medicine
researchProduct

2019

The widespread use of 68Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to 68Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr3]octreotide (TOC), a somatostatin subtype 2 receptor (SST2)-targeting vector for imaging and functional characterisation of SSTR2 expressing tumours. The radiopharmaceutical precursor, DATA-TOC, was synthe…

PET-CTmedicine.diagnostic_test010405 organic chemistrybusiness.industrySomatostatin receptorRadiochemistry010402 general chemistry01 natural sciences0104 chemical sciencesPharmacokineticsIn vivoPositron emission tomographyMedicineSomatostatin receptor 2Radiology Nuclear Medicine and imagingbusinessReceptormCherryEJNMMI Research
researchProduct

An Unusual Presentation of Zollinger-Ellison Syndrome

2013

Abstract Zollinger-Ellison syndrome is an often progressive, persistent and frequently life-threatening disease, described for the first time as characterized by ulceration of the upper jejunum, hypersecretion of gastric acid and non-beta islet cell tumors of the pancreas; this syndrome is due to the hypersecretion of gastrin. We report a case of Zollinger-Ellison syndrome presenting as severe esophagitis evolving in stenosis, which demonstrates how a delayed diagnosis may induce risk of disease spreading. In this setting new diagnostic approaches, such as somatostatin receptor scanning and positron emission tomography with 68 Ga-labeled octreotide, could be particularly useful, as well as …

Positron emission tomographyPathologymedicine.medical_specialtySettore MED/09 - Medicina InternaOctreotideZollinger-Ellison syndromePublished online: January 2013medicinelcsh:RC799-869GastrinSomatostatin receptorbusiness.industryGastroenterologyZollinger ellison. severe esophagitismedicine.diseaseZollinger-Ellison syndromemedicine.anatomical_structureOctreoscanRadionuclide therapyGastric acidlcsh:Diseases of the digestive system. GastroenterologyEsophageal stricturesPancreasbusinessEsophagitismedicine.drugCase Reports in Gastroenterology
researchProduct